Femasys

Femasys EBITDA per Employee

The EBITDA per Employee of Femasys (FEMY) as of Oct 20, 2026 is -495,212.65 USD. In the previous year, EBITDA per Employee was -514,367.79 USD — a change of -3.72% (higher).

EBITDA per Employee

-495,212.65USD

YoY

-3.72%

Last updated:

EBITDA per Employee of Femasys is 2025 -495,212.65 USD. EBITDA per Employee of Femasys was 2024 -514,367.79 USD. It decreases by -3.72% higher compared to the previous year.

The Femasys EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-323,740.71 USD
Jan 1, 2020
-183,915.97 USD
Jan 1, 2021
-227,847.18 USD
Jan 1, 2022
-324,713.65 USD
Jan 1, 2023
-412,497.50 USD
Jan 1, 2024
-514,367.79 USD
Jan 1, 2025
-495,212.65 USD
The Femasys EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-495,212.65USD-3.72%
-514,367.79USD+24.70%
-412,497.50USD+27.03%
-324,713.65USD+42.51%
-227,847.18USD+23.89%
-183,915.97USD-43.19%
-323,740.71USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Femasys Stock analysis

What does Femasys do? Femasys, Inc. generates revenue through the development and commercialization of its two lead product candidates, FemBloc and FemaSeed, alongside its FemEMB technology platform. FemBloc, a permanent birth control solution featuring dual intrauterine directional delivery with a degradable biopolymer, targets women seeking non-surgical contraceptive options. FemaSeed, an artificial insemination infertility treatment with single intrauterine directional delivery, addresses fertility challenges for patients. The FemEMB platform, designed for tissue sampling in physician offices, complements these products by enhancing diagnostic capabilities for women's health. These solutions are marketed to healthcare providers and clinics globally, focusing on improving patient care and health economics through office-based, non-surgical interventions. The company's revenue streams are derived from the sale of FemBloc, FemaSeed, and FemEMB to medical institutions and healthcare professionals. FemBloc targets women requiring permanent contraception, while FemaSeed serves patients with infertility issues. FemEMB supports physicians in conducting tissue sampling during routine office visits. The firm’s focus on non-surgical, office-based solutions positions it to serve a growing segment of women seeking accessible reproductive healthcare without invasive procedures. This approach aligns with the company’s mission to improve health economics by reducing the need for hospital-based interventions. Femasys, Inc. leverages its product portfolio to address key reproductive health needs through innovative, non-surgical technologies. FemBloc and FemaSeed are positioned as advanced alternatives to traditional methods, offering targeted delivery systems for contraception and fertility treatment. The FemEMB platform further enhances the company’s offerings by integrating diagnostic tools into standard office care. These products are sold to healthcare providers who serve women worldwide, emphasizing accessibility and improved patient outcomes. The company’s strategy centers on delivering solutions that meet the evolving demands of women’s healthcare in a cost-effective manner. Femasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Femasys stock

EBITDA per Employee of Femasys is -495,212.65 USD in 2025.

EBITDA per Employee of Femasys changed from -514,367.79 USD to -495,212.65 USD, representing a -3.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Femasys since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Femasys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Femasys

All Key Metrics — Femasys